Options Data for US Stocks: End-of-Day and Historical Learn more

Merck KGaA ADR icon

Merck KGaA ADR (MKKGY PINK) stock market data APIs

$31.5528 0.08(0.3%)
as of September 8, 2026
Try our APIs with free plan!

Merck KGaA ADR Financial Data Overview

Price chart is built with Anychart

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a sub

Prev. Close 31.5528
Open 31.6306
High 31.922
Low 31.5327
52 wk Range 23.2693-34.19
Market Cap 68 499 M
P/E Ratio 25.0079
Shares Outstanding 646 M
Revenue 21 135 M
EPS 0.4988
Dividends (Yield) 0.0163
Beta 0.805

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.


Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Merck KGaA ADR data using free add-ons & libraries


Get Merck KGaA ADR Fundamental Data

Merck KGaA ADR logo

Merck KGaA ADR Fundamental data includes:

  • Net Revenue: 21 135 M
  • EBITDA: 5 587 M
  • Earnings Per Share: 1
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Merck KGaA ADR Earnings data

Corporate Events Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2026-08-06
  • EPS/Forecast: 0.4712
GET THE PACKAGE

Get Merck KGaA ADR End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Merck KGaA ADR News

Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others New

Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others

Company Logo 500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein MarketResea...

IVD Raw Material Market Report Now Available — Forecasts Market Growth from $21.5B (2026) to $31.1B by 2031, Profiling Merck KGaA, Thermo Fisher, Bio-Techne, Fapon Biotech, and 21 Other Key Players

IVD Raw Material Market Report Now Available — Forecasts Market Growth from $21.5B (2026) to $31.1B by 2031, Profiling Merck KGaA, Thermo Fisher, Bio-Techne, Fapon Biotech, and 21 Other Key Players

Company Logo 500-Page Report Ranks Suppliers by Competitive Position Across the Company Evaluation Matrix as Infectious Disease Testing Drives the Largest Application Segment IVD Raw Material Market...

Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease

Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease

Funding brings total capital raised to $62 million as the Company expands pharmaceutical co-development partnerships and accelerates the Hybrid Drug category NEW YORK, Aug. 12, 2026 /PRNewswire/ -- R...

[Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global gRNA Market size & share revenue was valued a...

Get Merck KGaA ADR fresh news feed via Financial News API

Corporate Events Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Live chat support

Send the request

Leave your email and our team will contact you ASAP.